{"entity":{"id":"nct07192107","kind":"trial","name":"A Study of MHB042C in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of MHB042C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","summary":"A Study of MHB042C in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07192107 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants planned, started 2025-11-27 and due to reach its primary completion in 2029-10. Interventions recorded: MHB042C for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07192107","url":"https://clinicaltrials.gov/study/NCT07192107"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07192107","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB042C for Injection in Patients With Advanced Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","enrolled":200,"outcomes":[]},"route":"/trials/nct07192107/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}